Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

Martinez-Navio JM, Desrosiers RC.

J Virol. 2012 Dec;86(23):12484-93. doi: 10.1128/JVI.01959-12. Epub 2012 Sep 19.

2.

Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Yuste E, Bixby J, Lifson J, Sato S, Johnson W, Desrosiers R.

J Virol. 2008 Dec;82(24):12472-86. doi: 10.1128/JVI.01382-08. Epub 2008 Oct 1.

3.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

4.
5.

Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.

White E, Wu F, Chertova E, Bess J, Roser JD, Lifson JD, Hirsch VM.

J Virol. 2018 Jan 17;92(3). pii: e01688-17. doi: 10.1128/JVI.01688-17. Print 2018 Feb 1.

6.

Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Postler TS, Martinez-Navio JM, Yuste E, Desrosiers RC.

J Virol. 2012 Jan;86(2):1145-57. doi: 10.1128/JVI.06463-11. Epub 2011 Nov 9.

8.
9.

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS.

J Virol. 2012 Jul;86(13):7052-9. doi: 10.1128/JVI.00107-12. Epub 2012 Apr 24.

10.

Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.

Kodama T, Burns DP, Silva DP, Veronese FD, Desrosiers RC.

J Virol. 1991 Apr;65(4):2010-8.

11.

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.

12.

Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.

Sugimoto C, Nakayama EE, Shioda T, Villinger F, Ansari AA, Yamamoto N, Suzuki Y, Nagai Y, Mori K.

J Gen Virol. 2008 Feb;89(Pt 2):554-66. doi: 10.1099/vir.0.83186-0.

PMID:
18198387
13.
14.

Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Jurkiewicz E, Hunsmann G, Schäffner J, Nisslein T, Lüke W, Petry H.

J Virol. 1997 Dec;71(12):9475-81.

15.

Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.

Silvera P, Flanagan B, Kent K, Rud E, Powell C, Corcoran T, Bruck C, Thiriart C, Haigwood NL, Stott EJ.

AIDS Res Hum Retroviruses. 1994 Oct;10(10):1295-304.

PMID:
7848685
16.

Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, Keele BF, Robinson JE, Li H, Hahn BH, Shaw GM, Bar KJ.

J Virol. 2013 May;87(10):5477-92. doi: 10.1128/JVI.03419-12. Epub 2013 Mar 6.

17.

Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development.

Petry H, Dittmer U, Jones D, Farrar G, Wachter H, Fuchs D, Nisslein T, Jurkiewicz E, Hunsmann G, Stahl-Hennig C, Lüke W.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):441-50.

PMID:
9859957
18.

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.

Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L.

J Virol. 2010 Apr;84(7):3443-53. doi: 10.1128/JVI.02617-09. Epub 2010 Jan 27.

19.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

20.

Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.

Faith SA, Wu Y, Kuhrt D, Steckbeck JD, Craigo JK, Clements JE, Cole KS.

Virology. 2010 Apr 25;400(1):86-92. doi: 10.1016/j.virol.2010.01.014. Epub 2010 Feb 11.

Supplemental Content

Support Center